Galena Biopharma (GALE) Tops Q1 EPS by 1c

Galena Biopharma (NASDAQ: GALE) reported Q1 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $2.75 million versus the consensus estimate of $3.47 million.

For earnings history and earnings-related data on Galena Biopharma (GALE) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Change in Nonfarm Payrolls (Sep) 29K vs 90K Expected, Unemployment Rate 4.2%
• Freeport Q3 2026 copper output meets targets; gold sales deferred